---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-032803"
form_type: "8-K"
ticker: null
cik: "0001855351"
company_name: "Sagaliam Acquisition Corp"
filed_at: "2023-09-15T23:59:59+00:00"
generated_at: "2026-06-10T16:42:25.950406+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sagaliam Acquisition Corp. signs business combination agreement with Enzolytics; receives Nasdaq delisting notice

## Summary
- Entered into definitive Business Combination Agreement to acquire Virogentics Inc. and Biogenysis Inc., operating subsidiaries of Enzolytics Inc. (OTC PK: ENZC).
- Combined company expected to trade on Nasdaq; no deal value disclosed in the filing.
- Received Nasdaq delinquency notice for failing to timely file Q1 2023 Form 10-Q and Q2 2023 Form 10-Q.
- Must submit compliance plan by Sept 25, 2023; if accepted, has until Nov 20, 2023 to regain compliance.
- Company cites need for additional time to finalize financial statements; auditors have not completed review.

## SEC filing metadata
- accession: 0001493152-23-032803
- form_type: 8-K
- cik: 0001855351
- company_name: Sagaliam Acquisition Corp
- filed_at: 2023-09-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855351/000149315223032803/0001493152-23-032803-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855351/000149315223032803/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-032803
- JSON: https://secwatch.observer/filing/0001493152-23-032803.json
- Plain text: https://secwatch.observer/filing/0001493152-23-032803.txt

## Key facts
- Listing & Compliance Notices
  Sagaliam Acquisition Corp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: late filing
  - Rules: 5250(c)(1)
  source text: August 23, 2023 due to the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”) as a result of the Company’s failure to timely file its Annual Report on Form 10-Q for the fiscal quarter ended June 30, 2023 (the “ Form 10-Q ”). The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “ SEC ”). The Notice states that since Nasdaq has not received the Company’s Form 10-Q for the period ended June 30, 2023, and because the Company remains delinquent in filing its Form 10-Q for the period ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855351/000149315223032803/0001493152-23-032803-index.htm
- Material Agreements
  Sagaliam Acquisition Corp entered into Business Combination Agreement with Enzolytics Inc., Virogentics Inc., Biogenysis Inc. (effective 2023-09-15).
  - Action: entry
  - Agreement: merger
  - Counterparty: Enzolytics Inc., Virogentics Inc., Biogenysis Inc.
  - Effective: 2023-09-15
  source text: On September 15, 2023, Sagaliam Acquisition Corp., a Delaware corporation (“Sagaliam”), entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”) by and among Sagaliam Acquisition Corp. (“PubCo”), Enzolytics Inc. (OTC PK: ENZC), Virogentics Inc. (“VGEN”), and Biogenysis Inc. (“BGEN”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855351/000149315223032803/0001493152-23-032803-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.